"Pharmacoepidemiology" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The science concerned with the benefit and risk of drugs used in populations and the analysis of the outcomes of drug therapies. Pharmacoepidemiologic data come from both clinical trials and epidemiological studies with emphasis on methods for the detection and evaluation of drug-related adverse effects, assessment of risk vs benefit ratios in drug therapy, patterns of drug utilization, the cost-effectiveness of specific drugs, methodology of postmarketing surveillance, and the relation between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines. (Pharmacoepidemiol Drug Saf 1992;1(1); J Pharmacoepidemiol 1990;1(1))
| Descriptor ID |
D017891
|
| MeSH Number(s) |
H01.158.703.045 H02.403.720.500.650 H02.628.413
|
| Concept/Terms |
Pharmacoepidemiology- Pharmacoepidemiology
- Pharmaceutical Epidemiology
- Epidemiologies, Pharmaceutical
- Pharmaceutical Epidemiologies
- Epidemiology, Pharmaceutical
|
Below are MeSH descriptors whose meaning is more general than "Pharmacoepidemiology".
Below are MeSH descriptors whose meaning is more specific than "Pharmacoepidemiology".
This graph shows the total number of publications written about "Pharmacoepidemiology" by people in this website by year, and whether "Pharmacoepidemiology" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacoepidemiology" by people in Profiles.
-
Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection. Ann Epidemiol. 2018 11; 28(11):808-811.
-
Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studies. Pharmacoepidemiol Drug Saf. 2018 07; 27(7):781-788.
-
Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
-
Validation of an algorithm to identify antiretroviral-na?ve status at time of entry into a large, observational cohort of HIV-infected patients. Pharmacoepidemiol Drug Saf. 2013 Sep; 22(9):1019-25.
-
Clinical prediction rule to identify high-risk inpatients for adverse drug events: the JADE Study. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1221-6.
-
Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007 Sep; 2(3):177-85.
-
Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf. 2001 Mar-Apr; 10(2):113-9.
-
Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. Drugs Aging. 1995 Aug; 7(2):117-30.